Class summary at a glance.

Every drug in the Long-Acting Muscarinic Antagonist (Bronchodilator) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $2.03Bcombined across class
Total Rx claims: 3.0M928K unique beneficiaries
Generic mfrs (active): 1across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Tiotropium

Brand: Spiriva · 3.0M Part D claims (CY24) · 928K beneficiaries · First FDA approval: 2005-10-11

1 generic mfrs 0 plans require PA

Low NADAC$10.62

→

Avg plan cost$11.15

Part D spend $2.03B 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.